Alluvi, known as BI 4744, presents a promising development in obesity care. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates impressive https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/